Palaniappa Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 04-12-2024
- Paid Up Capital ₹ 0.25 M
as on 04-12-2024
- Company Age 16 Year, 1 Month
- Last Filing with ROC 31 Mar 2020
- Satisfied Charges ₹ 4.92 Cr
as on 04-12-2024
- Revenue -25.64%
(FY 2020)
- Profit -22.39%
(FY 2020)
- Ebitda -8.30%
(FY 2020)
- Net Worth 4.27%
(FY 2020)
- Total Assets -6.87%
(FY 2020)
About Palaniappa Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.25 M.
The company has closed loans amounting to ₹4.92 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Nadarajan Narayanan and Lakshminarayanan Malini serve as directors at the Company.
- CIN/LLPIN
U33110TN2008PTC069795
- Company No.
069795
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Nov 2008
- Date of AGM
30 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Madurai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Palaniappa Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nadarajan Narayanan  | Director | 31-Mar-2009 | Current |
| Lakshminarayanan Malini | Director | 01-Jun-2015 | Current |
Financial Performance of Palaniappa Pharma.
Palaniappa Pharma Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 25.64% decrease. The company also saw a substantial fall in profitability, with a 22.39% decrease in profit. The company's net worth moved up by a moderate rise of 4.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Palaniappa Pharma?
In 2020, Palaniappa Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Tamilnad Mercantile Bank Limited Creation Date: 04 Aug 2021 | ₹1.65 M | Satisfied |
Tamilnad Mercantile Bank Limited Creation Date: 10 Jun 2020 | ₹5.00 M | Satisfied |
Tamilnad Mercantile Bank Limited Creation Date: 05 Feb 2020 | ₹1.50 M | Satisfied |
How Many Employees Work at Palaniappa Pharma?
Palaniappa Pharma has a workforce of 11 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Palaniappa Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Palaniappa Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
